HISTOPATHOLOGY AND MOLECULAR PATHOLOGY

该项目评估端点以确定状态和 利用组织病理学的胃粘膜病变的演变， 免疫化学和分子生物学技术。 8例活检 哥伦比亚和新西兰患者胃粘膜中的特定位置 新奥尔良将被分配到一个全球诊断的基础上最先进的 病变和以下参数的详细评估” 多形核细胞和单核白细胞浸润， 上皮细胞、萎缩、化生、粘蛋白、刘易斯抗体、Ki 67 标记指数，诱导型一氧化氮合酶，硝基酪氨酸，细胞凋亡， p53异常、TPR-MET表达和微卫星不稳定。 利用这些标记的技术描述于 这些都是调查人员非常熟悉的。 不同 其他项目中描述的干预措施，特别是抗螺杆菌 幽门螺杆菌治疗和抗氧化剂的给药旨在改变 癌前过程中的表型事件。 选择的标记是 旨在评估这些变化与最先进的技术， 和介入后的活组织检查 将对每个标记进行评价 独立地和它们的组合将被设计和测试， 制定改变癌前过程的措施， 和综合得分。

This project evaluates the endpoints to determine the status and the evolution of the lesions of the gastric mucosa utilizing histopathological, immunochemical and molecular biology techniques. Biopsies taken from 8 specific locations in the gastric mucosa in patients from Colombia and New Orleans will be assigned a global diagnosis based on the most advanced lesion and detailed assessment of the following parameters" polymorphonuclear, and mononuclear leukocytic infiltration, damage to epithelial cells, atrophy, metaplasia, mucins, Lewis antibodies, Ki 67 labelling index, inducible nitric oxide synthase, nitrotyrosine, apoptosis, p53 abnormalities, TPR-MET expression and microsatellite destabilization. The techniques for the utilization of these markers are described in the text and are thoroughly familiar to the investigators. The different interventions described in the other projects, especially anti-Helicobacter pylori therapy and administration of antioxidants are directed to modify the phenotypic events in the precancerous process. The markers chosen are intended to evaluate those changes with state of the art techniques in pre- and post-intervention biopsies. Each marker will be evaluated independently and combinations of them will be designed and tested to develop measures of change of the precancerous process in terms of single and combined scores.